🔗 Share this article

The recently developed medications for gonorrhoea in many years are being viewed as a "significant breakthrough" in the fight against drug-resistant strains of the infection, according to scientists.

A Worldwide Health Concern

The sexually transmitted infection are on the rise worldwide, with data suggesting in excess of 82 million new cases each year. Especially elevated rates are reported in Africa and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune step in the context of rising global incidence, the spread of superbugs and the extremely scarce therapeutic options presently on offer.”

Health officials are particularly alarmed about the surge in treatment-resistant strains. The WHO has classified it as a "priority pathogen". Ongoing monitoring showed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Drugs Secure Approval

One new antibiotic, marketed under the name Nuzolvence, was authorized by the US FDA in mid-December for use against gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts hope that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the drugmaker GSK, also received approval in close succession. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This milestone marks a huge turning point in the treatment of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Testing Data and Worldwide Availability

According to results published in a prominent scientific publication, zoliflodacin successfully treated over nine in ten of uncomplicated infections. This establishes an equal footing with the existing first-line therapy, which combines two antibiotics. The research involved over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the rights to license and sell the drug in a wide range of regions with limited resources.

Doctors on the front lines have expressed positive views. Having a single-dose, oral treatment such as this is described as a "game-changer" for managing the epidemic. This is deemed essential to alleviate the strain of the illness for individuals and to stop the proliferation of extremely resistant gonorrhoea worldwide.